Skip to main content
Clinical Trials/IRCT20200413047063N3
IRCT20200413047063N3RecruitingPhase 1

Safety of injection of placental mesenchymal stem cell derived exosomes for Treatment of resistant perianal fistula in Crohn's patients

Omid cell and tissue Company0 sites20 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Phase 1
Status
Recruiting
Sponsor
Enrollment
20

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
no limit to no limit (—)
Sex
All

Inclusion Criteria

  • Patient with Crohn or other IBD disease, resistance to a 6 month period of treatment with anti TNF, without any success
  • Patient with Crohn or other IBD disease, resistance to a 6 month period of treatment with infliximab, without any success
  • Patient with Crohn or other IBD disease, resistance to a 6 month period of treatment with infliximab and anti TNF, without any success
  • Patient with Crohn or other IBD disease, resistance to a 6 month period of drug therapy and surgery, without any success

Exclusion Criteria

  • Patients with immunodeficiency disorders/disease
  • Patients with history of malignancy
  • Patient dissatisfaction
  • Patients in need of surgery
  • Severe co-morbidities (e.g., renal failure, liver failure, etc.)
  • Cerebral Damage

Investigators

Sponsor
Omid cell and tissue Company

Similar Trials